TScan Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TScan Therapeutics's estimated annual revenue is currently $18.9M per year.
- TScan Therapeutics's estimated revenue per employee is $128,639
- TScan Therapeutics's total funding is $137.5M.
Employee Data
- TScan Therapeutics has 147 Employees.
- TScan Therapeutics grew their employee count by 23% last year.
TScan Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is TScan Therapeutics?
Harnessing novel T cell systems to extend the promise of immunotherapy
keywords:N/A
$137.5M
Total Funding
147
Number of Employees
$18.9M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TScan Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Technical Operations and Quality | Reveal Email/Phone |
3 | VP Clinical Operations | Reveal Email/Phone |
4 | Director Head FP&A | Reveal Email/Phone |
5 | Associate Director, Cell Therapy Analytical Development | Reveal Email/Phone |
6 | Manufacturing Manager | Reveal Email/Phone |
7 | Associate General Counsel | Reveal Email/Phone |
8 | Sr. Director, New Product Planning | Reveal Email/Phone |
9 | SVP Human Resources | Reveal Email/Phone |
10 | Scientist - Preclinical | Reveal Email/Phone |
TScan Therapeutics News
HC Wainwright reissued a buy rating and issued a $21.00 price target on shares of TScan Therapeutics in a report on Thursday, March 10th. One...
The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) increased by 17.83% in the most recent trading session. This is why.
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company...
Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates, TSC-100 and TSC-101 WALTHAM, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- TScan Thera ...
TScan Therapeutics, a Waltham, Mass.-based biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies in oncology, closed a $100m Series C financing. Backers included new investors BlackRock, RA Capital Management, and two undisclosed healthcare-fo ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.5M | 147 | 34% | $333M |
#2 | $28.7M | 148 | -10% | $227M |
#3 | $28.9M | 149 | 18% | $125.4M |
#4 | $34.4M | 149 | 0% | N/A |
#5 | $23.9M | 150 | 8% | N/A |